9177 Lipocalin-2 is an important predictor of susceptibility to therapy with pemetrexed in non-small cell lung cancers

M.F.Wu; J.L.Ko

首页> 外文期刊>European Journal of Cancer Supplements >9177 Lipocalin-2 is an important predictor of susceptibility to therapy with pemetrexed in non-small cell lung cancers

【24h】

9177 Lipocalin-2 is an important predictor of susceptibility to therapy with pemetrexed in non-small cell lung cancers

机译：9177 Lipocalin-2是非小细胞肺癌培美曲塞治疗敏感性的重要预测指标

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共1页
作者
M.F.Wu; J.L.Ko;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 9177 Lipocalin-2 is an important predictor of susceptibility to therapy with pemetrexed in non-small cell lung cancers [J] . M.F.Wu, J.L.Ko European Journal of Cancer Supplements . 2009,第2期

机译：9177 Lipocalin-2是非小细胞肺癌培美曲塞治疗敏感性的重要预测指标
2. Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902 [J] . Kanazawa Kenya, Yokouchi Hiroshi, Wang Xintao, Cancer chemotherapy and pharmacology. . 2014,第6期

机译：卡铂和培美曲塞作为一线化疗治疗非鳞状非小细胞肺癌的第二阶段试验，以及与培美曲塞代谢相关的功效/毒性和遗传多态性之间的相关性：北海道肺癌临床研究组试验（HOT）0902
3. Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer [J] . Jo Jaemin, Kim Se Hyun, Kim Yu Jung, Yonsei Medical Journal . 2018,第2期

机译：培美曲塞为基础的化疗与非培美曲塞为基础的化疗在晚期ALK +非小细胞肺癌中的疗效比较
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Predictors of changes in health-related quality of life during chemotherapy in an advanced non-small cell lung cancer patient population [D] . Shallwani, Shirin Mehdi 2010

机译：非小细胞肺癌晚期患者化疗期间健康相关生活质量变化的预测因子
6. Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based chemotherapy in patients with non-squamous non-small cell lung cancer [O] . Xiaoxia Chen, Fei Zhou, Xuefei Li, 2020

机译：叶酸受体阳性循环肿瘤细胞作为基于培美曲塞一线化疗对非鳞状非小细胞肺癌患者疗效的预测生物标志物
7. Correction: Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed [O] . Nasha Zhang, Li Kong, Fang Shi, 2017

机译：校正：血清癌胚抗原的动力学变化可以早期预测蜂巢培养治疗过程中转移性非小细胞肺癌患者的进展。

9177 Lipocalin-2 is an important predictor of susceptibility to therapy with pemetrexed in non-small cell lung cancers

著录项

相似文献

相关主题

期刊订阅